Trafalgar International (GCAN) Change in Account Payables (2019 - 2026)
Trafalgar International (GCAN) posted Change in Account Payables of -$1000.0 for Q1 2026, down 198.51% on a QoQ basis from -$335.0 in Q4 2025, and down 706.06% year-over-year from $165.0 in Q1 2025.
Powered by 
Analysis
Trafalgar International (GCAN) Change in Account Payables (2019 - 2026) Analysis & Trends
Trafalgar International has reported Change in Account Payables for 8 years, with the latest figure at -$1000.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables fell 706.06% year-over-year to -$1000.0 in Q1 2026; TTM through Mar 2026 was -$530.0, a 129.69% decrease from a year earlier, with the FY2025 full-year figure at $635.0, down 64.43% from the prior year.
- Change in Account Payables was -$1000.0 for Q1 2026 at Trafalgar International, down from -$335.0 in the prior quarter.
- The five-year high for Change in Account Payables was $5951.0 in Q3 2022, with the low at -$10259.0 in Q1 2023.
- Average Change in Account Payables over 5 years is -$246.53, with a median of $165.0 recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables tumbled 920.72% in 2023, then surged 157.95% in 2024.
- Over 5 years, Change in Account Payables stood at $1954.0 in 2022, then soared by 40.94% to $2754.0 in 2023, then tumbled by 46.95% to $1461.0 in 2024, then slumped by 122.93% to -$335.0 in 2025, then tumbled by 198.51% to -$1000.0 in 2026.
- The last three Change in Account Payables figures came in at -$1000.0 (Q1 2026), -$335.0 (Q4 2025), and $2056.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 5.03 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 22.43 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | -1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -335.00 |
| Sep 30, 2025 | 2,056.00 |
| Jun 30, 2025 | -1,251.00 |
| Mar 31, 2025 | 165.00 |
| Dec 31, 2024 | 1,461.00 |
| Sep 30, 2024 | 1,159.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | 165.00 |
| Dec 31, 2023 | 2,754.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -652.00 |
| Mar 31, 2023 | -10,259.00 |
| Dec 31, 2022 | 1,954.00 |
| Sep 30, 2022 | 5,951.00 |
| Jun 30, 2022 | -4,609.00 |
| Mar 31, 2022 | 1,250.00 |
| Dec 31, 2021 | 3,263.00 |
| Sep 30, 2021 | 6,517.00 |
| Jun 30, 2021 | -2,568.00 |